Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
February 19 2019 - 6:00AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by complement-mediated diseases,
today announced that Joseph Truitt, President and Chief Executive
Officer of Achillion, will present at the SVB Leerink 8th Annual
Global Healthcare Conference on Thursday, February 28, 2019, at 2PM
ET at the Lotte New York Palace, New York, NY.
The live audio and subsequent archived webcasts
of the Company's presentation will be accessible from the Company's
investor relations website, http://ir.achillion.com. The audio
recording will be archived for 30 days following the live
presentation. Please connect to Achillion's website several minutes
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary.
About Achillion
PharmaceuticalsAchillion Pharmaceuticals,
Inc. (Nasdaq: ACHN) is a clinical-stage biopharmaceutical
company focused on advancing its oral small molecule
complement inhibitors into late-stage development and
commercialization. Achillion is initially focusing its drug
development activities on complement-mediated diseases where there
are no approved therapies or where existing therapies are
inadequate for patients. Potential indications being evaluated for
its compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3
glomerulopathy (C3G), and immune complex mediated
membranoproliferative glomerulonephritis (IC-MPGN). Each of the
product candidates in the Company’s oral small molecule portfolio
was discovered in its laboratories and is wholly owned. To
advance its investigational product candidates into Phase 3
clinical trials and commercialization, the Company plans to work
closely with key stakeholders including healthcare professionals,
patients, regulators and payors. More information is available
at http://www.achillion.com.
Investors:Brian Di DonatoChief Financial
Officer Achillion Pharmaceuticals, Inc.Tel. (215)
709-3032bdidonato@achillion.com
Media:Jon PappasMedia RelationsW2O GroupTel.
(646) 847-0303jpappas@w2ogroup.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024